BioInvent International AB (publ) (LON: 0H22)

Market Cap	137.75M
Revenue (ttm)	2.84M
Net Income (ttm)	-30.14M
Shares Out	n/a
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220
Average Volume	562
Open	44.54
Previous Close	44.54
Day's Range	44.54 - 44.54
52-Week Range	14.60 - 44.54
Beta	0.38
RSI	21.13
Earnings Date	Feb 27, 2025

About BioInvent International AB

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 111
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H22

Financial Performance

In 2023, BioInvent International AB's revenue was 71.46 million, a decrease of -78.09% compared to the previous year's 326.13 million. Losses were -330.30 million, 677.1% more than in 2022.

Financial numbers in SEK